Last reviewed · How we verify
LY3009104
At a glance
| Generic name | LY3009104 |
|---|---|
| Also known as | Baricitinib, baricitinib, Janus Kinase (JAK)1/JAK2 Inhibitor, JAK1/2 Inhibitor, INCB028050 |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis (PHASE1)
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (PHASE3)
- A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) (PHASE3)
- Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) (PHASE2)
- Baricitinib for Reduction of HIV - CNS (PHASE2)
- Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study (PHASE2)
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3009104 CI brief — competitive landscape report
- LY3009104 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI